UNSPSC 51183903: Tesaglitazar

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6734037O3L. European Medicines Agency schedules Tesaglitazar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25217. Tesaglitazar generally arises in the molecular formula C20H24O7S.

The term TESAGLITAZAR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations, for tariff and trade purposes, schedule tesaglitazar under HS 29189900 and SITC 51396. As of Q4 2014, TESAGLITAZAR remains US FDA's Preferred Term for this commodity. Tesaglitazar bears US NLM identifiers UMLS ID C1570259 and NCI Concept Code C75985. SMILES: S(=O)(=O)(OC1CCC(CCOC2CCC(CC(OCC)C(=O)O)CC2)CC1)C.

UNSPSC 51183903 Tesaglitazar is a Commodity code identifying a specific pharmaceutical product within state and local government procurement. Recent activity under this code shows minimal direct procurement; the single identified opportunity involves a broader generic multi-source pharmaceutical RFP rather than tesaglitazar-specific solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and over-the-counter products distributed across participating state and local facilities including Oregon. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two of the three wholesalers with chargeback systems in place, and carry comprehensive insurance including $5 million commercial general liability coverage. Pricing evaluation weights 75 percent to price competitiveness, with 10 percent on fixed pricing, and 5 percent each on administrative fee data format compliance, EDI capability, and willingness to accept a 3 percent administrative fee. Contract terms run two years for new vendors, with optional MMCAP extensions, or through June 30, 2028, for incumbent amendments.

MMCAP serves as the primary issuing body identified in recent activity, operating as a cooperative purchasing vehicle spanning multiple states. The RFP closing date was March 26, 2026, with a question cutoff of February 18, 2026. Awarded vendors are required to provide products by July 1, 2026, effective date. Geographic coverage extends across Minnesota and Oregon at minimum, with potential for broader multistate participation through MMCAP's cooperative structure. Performance penalties of $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, or improper class-of-trade denials. No specific set-aside restrictions or disadvantaged-enterprise designations were identified in the documentation. The solicitation does not disclose award values or budget ranges.